What is Prestige Consumer Healthcare Inc.'s earnings per share (EPS)?

Prestige Consumer Healthcare Inc. (PBH) reported diluted earnings per share of $3.91 for fiscal year 2026. This represents a -8.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Prestige Consumer Healthcare Inc. (PBH) Financials

PBH

Trailing 12 months to June 30, 2026

Revenue $1.1B -1.4% YoY

Net Income $172.0M -19.2% YoY

EPS (Diluted) $3.57 -16.4% YoY

Free Cash Flow $235.4M -12.1% YoY

Market Cap $2.3B as of Oct 8, 2026

Price / Sales 2.0x on $1.1B revenue, trailing 12 months to June 30, 2026

Price / Earnings 13.1x on $172.0M net income, trailing 12 months to June 30, 2026

Price / Book 1.2x on $1.9B equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBH SEC filings page.

Prestige Consumer Healthcare Inc. (PBH) reported $1.1B in revenue over the twelve months to Jun 30, 2026, down 1.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PBH FY2026 2026-10-03

Cash generation remains durable, but FY2026 shows weaker sales absorption and a renewed preference for share repurchases.

Net income fell to $190M in FY2026 while operating cash flow reached $258M, meaning reported earnings weakened without a corresponding deterioration in cash conversion. Because free cash flow remained close to operating cash flow, the business is still converting much of its operating output after reinvestment, although the figures do not identify whether working capital or noncash expenses drove the gap.

Revenue fell 4.3% in FY2026. Net margin narrowed from 18.9% to 17.5%, indicating that lower volume was not fully offset by cost flexibility. Gross margin also eased from 55.8% to 54.7%, so pressure was not confined to expenses below gross profit.

Debt-to-equity declined from 0.9x to 0.5x, making the balance sheet less dependent on borrowing. That deleveraging coincided with $156M of repurchases and a 4.1% reduction in shares, so capital returns did not prevent lower leverage.

Financial Health Signals

Financial Health Score 61/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Prestige Consumer Healthcare Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Prestige Consumer Healthcare Inc. has an operating margin of 28.4%, meaning the company retains $28 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is down from 29.6% the prior year.

Growth

Prestige Consumer Healthcare Inc.'s revenue declined 4.3% year-over-year, from $1.1B to $1.1B. This contraction results in a growth score of 26/100.

Leverage

Prestige Consumer Healthcare Inc. has elevated debt relative to equity (D/E of 0.53), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 24/100, reflecting increased financial risk.

Liquidity

With a current ratio of 3.57, Prestige Consumer Healthcare Inc. holds $3.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 84/100.

Cash Flow

Prestige Consumer Healthcare Inc. converts 22.6% of revenue into free cash flow ($246.4M). This strong cash generation earns a score of 88/100.

Returns

Prestige Consumer Healthcare Inc.'s ROE of 10.1% shows moderate profitability relative to equity, earning a score of 62/100. This is down from 11.7% the prior year.

Altman Z-Score Grey Zone

2.25

Prestige Consumer Healthcare Inc. scores 2.25, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Prestige Consumer Healthcare Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.35x

For every $1 of reported earnings, Prestige Consumer Healthcare Inc. generates $1.35 in operating cash flow ($257.6M OCF vs $190.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

7.31x

Prestige Consumer Healthcare Inc. earns $7.31 in operating income for every $1 of interest expense ($309.4M vs $42.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$265.7M

YoY+6.5%

QoQ-5.6%

5Y CAGR-0.3%

10Y CAGR+2.4%

Prestige Consumer Healthcare Inc. generated $265.7M in revenue in Q1 2027. This represents an increase of 6.5% from the same quarter a year earlier. Against the prior quarter it is down 5.6%.

EBITDA

$61.3M

YoY-22.9%

QoQ-26.9%

5Y CAGR-9.1%

10Y CAGR+12.4%

Prestige Consumer Healthcare Inc.'s EBITDA was $61.3M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.9% from the same quarter a year earlier. Against the prior quarter it is down 26.9%.

Net Income

$29.2M

YoY-38.5%

QoQ-45.9%

5Y CAGR-12.8%

Prestige Consumer Healthcare Inc. reported $29.2M in net income in Q1 2027. This represents a decrease of 38.5% from the same quarter a year earlier. Against the prior quarter it is down 45.9%.

EPS (Diluted)

$0.61

YoY-35.8%

QoQ-46.0%

5Y CAGR-11.8%

Prestige Consumer Healthcare Inc. earned $0.61 per diluted share (EPS) in Q1 2027. This represents a decrease of 35.8% from the same quarter a year earlier. Against the prior quarter it is down 46.0%.

Cash & Balance Sheet

Free Cash Flow

$67.1M

YoY-14.2%

QoQ+78.3%

5Y CAGR-0.2%

10Y CAGR+2.9%

Prestige Consumer Healthcare Inc. generated $67.1M in free cash flow in Q1 2027, representing cash available after capex. This represents a decrease of 14.2% from the same quarter a year earlier. Against the prior quarter it is up 78.3%.

Cash & Debt

$89.1M

YoY-36.1%

QoQ+39.5%

5Y CAGR-11.4%

10Y CAGR+11.9%

Prestige Consumer Healthcare Inc. held $89.1M in cash against $2.0B in long-term debt as of Q1 2027.

Shares Outstanding

47M

YoY-3.7%

QoQ0.0%

5Y CAGR-1.1%

10Y CAGR-1.1%

Prestige Consumer Healthcare Inc. had 47M shares outstanding in Q1 2027. This represents a decrease of 3.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

51.2%

YoY-5.0pp

QoQ-0.7pp

5Y change-7.8pp

10Y change-6.8pp

Prestige Consumer Healthcare Inc.'s gross margin was 51.2% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Operating Margin

19.8%

YoY-9.0pp

QoQ-7.0pp

5Y change-14.2pp

10Y change+13.9pp

Prestige Consumer Healthcare Inc.'s operating margin was 19.8% in Q1 2027, reflecting core business profitability. This is down 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.0 percentage points.

Net Margin

11.0%

YoY-8.0pp

QoQ-8.2pp

5Y change-10.5pp

10Y change+13.6pp

Prestige Consumer Healthcare Inc.'s net profit margin was 11.0% in Q1 2027, showing the share of revenue converted to profit. This is down 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.2 percentage points.

Return on Equity

1.5%

YoY-1.0pp

QoQ-1.3pp

5Y change-2.6pp

10Y change+2.3pp

Prestige Consumer Healthcare Inc.'s ROE was 1.5% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Capital Allocation

Share Buybacks

YoY-100.0%

QoQ-100.0%

Prestige Consumer Healthcare Inc. repurchased no shares in Q1 2027. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Capital Expenditures

$3.7M

YoY+341.9%

QoQ-28.9%

5Y CAGR+19.8%

10Y CAGR+15.3%

Prestige Consumer Healthcare Inc. invested $3.7M in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 341.9% from the same quarter a year earlier. Against the prior quarter it is down 28.9%.

R&D Spending

Not reported for Q1 2027.

PBH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PBH quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.1B	$1.1B-4.3%	$1.1B+1.1%	$1.1B-0.2%	$1.1B+3.8%	$1.1B+15.2%	$943.4M-2.0%	$963.0M-1.3%	$975.8M-6.3%	$1.0B+18.0%	$882.1M+9.4%	$806.2M+13.0%	$713.5M+19.8%	$595.6M-3.4%	$616.9M+39.9%	$441.1M
Cost of Revenue	$513.5M	$493.1M-2.0%	$503.3M+0.5%	$500.9M-0.3%	$502.4M+7.8%	$466.2M+17.8%	$395.9M-3.6%	$410.8M-2.2%	$420.2M-9.6%	$464.7M+21.7%	$381.8M+12.6%	$339.0M	N/A	N/A	N/A	N/A
Gross Profit	$591.4M	$595.6M-6.1%	$634.5M+1.6%	$624.4M-0.1%	$625.3M+0.7%	$620.6M+13.4%	$547.5M-0.9%	$552.2M-0.6%	$555.6M-3.6%	$576.5M+15.2%	$500.3M+7.1%	$467.2M+15.0%	$406.2M+21.1%	$335.6M-2.4%	$343.7M+51.2%	$227.4M
SG&A Expenses	$131.3M	$116.4M+7.6%	$108.2M+1.9%	$106.2M-1.1%	$107.4M-0.1%	$107.5M+29.3%	$83.1M-6.7%	$89.1M-0.7%	$89.8M+5.1%	$85.4M-4.2%	$89.1M+23.1%	$72.4M-10.9%	$81.3M+67.6%	$48.5M-5.8%	$51.5M-9.2%	$56.7M
Operating Income	$290.2M	$309.4M-8.1%	$336.8M-1.7%	$342.4M+1627.7%	-$22.4M-106.8%	$329.9M+10.9%	$297.4M+2.1%	$291.2M+331.3%	$67.5M-68.7%	$215.5M+4.8%	$205.6M-21.0%	$260.3M+25.4%	$207.6M+10.0%	$188.6M-1.7%	$191.9M+86.6%	$102.8M
EBITDA	N/A	$340.7M-7.2%	$366.9M-1.6%	$373.1M+3554.3%	$10.2M-97.2%	$362.0M+10.5%	$327.6M+2.3%	$320.1M+222.5%	$99.3M-60.1%	$248.9M+7.5%	$231.4M-18.5%	$284.0M+26.1%	$225.3M+11.5%	$202.1M-1.5%	$205.1M+80.6%	$113.6M
Interest Expense	-$18.2M	-$42.3M-2452.2%	$1.8M-65.4%	$5.2M+18.2%	$4.4M-93.2%	$64.3M-21.9%	$82.3M-14.4%	$96.2M-8.4%	$105.1M-1.1%	$106.3M+13.6%	$93.5M+9.6%	$85.3M+4.9%	$81.3M+18.5%	$68.6M-18.7%	$84.4M+104.2%	$41.3M
Income Tax	$62.2M	$67.2M-3.4%	$69.6M+4.3%	$66.7M+674.4%	-$11.6M-120.3%	$57.1M+44.8%	$39.4M-19.3%	$48.9M+2267.2%	-$2.3M+99.0%	-$232.5M-660.8%	$41.5M-27.6%	$57.3M+16.4%	$49.2M+68.9%	$29.1M-28.1%	$40.5M+69.3%	$23.9M
Net Income	$172.0M	$190.3M-11.3%	$214.6M+2.5%	$209.3M+354.3%	-$82.3M-140.1%	$205.4M+24.7%	$164.7M+15.7%	$142.3M+497.4%	-$35.8M-110.5%	$339.6M+389.3%	$69.4M-30.5%	$99.9M+27.7%	$78.3M+7.8%	$72.6M+10.9%	$65.5M+76.0%	$37.2M
EPS (Basic)	N/A	$3.93-9.0%	$4.32+2.6%	$4.21+355.2%	-$1.65-140.3%	$4.09+24.7%	$3.28+16.7%	$2.81+507.2%	-$0.69-110.8%	$6.40+388.5%	$1.31-30.7%	$1.89+26.0%	$1.50+6.4%	$1.41+9.3%	$1.29+74.3%	$0.74
EPS (Diluted)	$3.57	$3.91-8.9%	$4.29+2.9%	$4.17+352.7%	-$1.65-140.8%	$4.04+24.3%	$3.25+16.9%	$2.78+502.9%	-$0.69-110.9%	$6.34+387.7%	$1.30-30.9%	$1.88+26.2%	$1.49+7.2%	$1.39+9.4%	$1.27+74.0%	$0.73
Diluted Shares (Avg)	N/A	49M-2.7%	50M-0.2%	50M+0.6%	50M-1.9%	51M+0.5%	51M-1.0%	51M-1.8%	52M-2.7%	54M+0.3%	53M+0.4%	53M+0.9%	53M+0.6%	52M+1.8%	51M+1.4%	51M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$265.7M+6.5%	$281.6M-5.0%	$283.4M-2.4%	$274.1M-3.4%	$249.5M-6.6%	$296.5M+7.0%	$290.3M+2.7%	$283.8M-0.9%
Cost of Revenue	$129.5M+18.6%	$135.3M+7.0%	$126.1M-2.5%	$122.5M-3.1%	$109.2M-9.8%	$126.5M+1.1%	$129.3M+3.6%	$126.4M+0.1%
Gross Profit	$136.2M-3.0%	$146.3M-13.9%	$157.4M-2.3%	$151.6M-3.7%	$140.3M-3.9%	$170.0M+12.0%	$161.0M+2.0%	$157.4M-1.6%
SG&A Expenses	$43.3M+52.2%	$30.3M+11.9%	$29.7M+13.3%	$28.0M+7.6%	$28.5M-1.6%	$27.1M+2.2%	$26.2M+0.7%	$26.1M+0.3%
Operating Income	$52.5M-26.8%	$75.5M-14.6%	$82.5M-10.3%	$79.7M-5.5%	$71.8M-0.4%	$88.4M+7.6%	$92.0M+5.9%	$84.3M-4.4%
EBITDA	$61.3M-22.9%	$83.8M-12.4%	$90.1M-8.9%	$87.3M-5.3%	$79.4M-0.9%	$95.7M+6.3%	$98.8M+4.6%	$92.3M-3.8%
Interest Expense	$13.9M+36.7%	-$11.4M+67.4%	-$10.7M-193.2%	-$10.0M-181.7%	$10.2M-22.3%	-$35.1M+24.9%	$11.5M-30.9%	$12.3M-30.2%
Income Tax	$9.4M-34.6%	$10.8M-54.5%	$15.1M-20.9%	$26.9M+55.7%	$14.3M+53.1%	$23.8M+33.4%	$19.1M+15.7%	$17.3M+2.6%
Net Income	$29.2M-38.5%	$53.9M+7.6%	$46.7M-23.5%	$42.2M-22.4%	$47.5M-3.3%	$50.1M+1.4%	$61.0M+15.1%	$54.4M+1.5%
EPS (Basic)	$0.61-36.5%	$1.13+11.9%	$0.98-20.3%	$0.86-21.8%	$0.96-2.0%	$1.01+1.0%	$1.23+15.0%	$1.10+1.9%
EPS (Diluted)	$0.61-35.8%	$1.13+11.9%	$0.97-20.5%	$0.86-21.1%	$0.95-3.1%	$1.01+3.1%	$1.22+15.1%	$1.09+1.9%
Diluted Shares (Avg)	48M-4.5%	N/A	48M-3.8%	49M-1.5%	50M-0.9%	N/A	50M-0.3%	50M-0.2%

Not reported in any period shown, so not listed: R&D Expenses.

PBH Balance Sheet

PBH quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$3.5B+2.7%	$3.4B+2.5%	$3.3B-1.1%	$3.4B-8.6%	$3.7B+7.0%	$3.4B-2.4%	$3.5B+2.1%	$3.4B-8.5%	$3.8B-3.9%	$3.9B+32.6%	$2.9B+11.6%	$2.6B+47.1%	$1.8B+3.2%	$1.7B-1.1%	$1.8B
Current Assets	$431.5M-3.8%	$448.3M+19.5%	$375.0M-4.3%	$391.7M+33.6%	$293.3M+8.7%	$269.8M-26.2%	$365.7M+21.5%	$300.9M-0.8%	$303.5M-9.3%	$334.4M+34.3%	$249.0M+23.5%	$201.7M+13.8%	$177.2M+7.9%	$164.2M+11.7%	$147.0M
Cash & Equivalents	$63.9M-34.8%	$97.9M+110.6%	$46.5M-20.6%	$58.5M+115.2%	$27.2M-15.8%	$32.3M-65.9%	$94.8M+244.2%	$27.5M-15.4%	$32.5M-22.2%	$41.9M+53.7%	$27.2M+27.7%	$21.3M-24.8%	$28.3M+80.8%	$15.7M-17.6%	$19.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$159.1M+7.7%	$147.7M+6.5%	$138.7M-14.4%	$162.1M+34.7%	$120.3M+4.7%	$115.0M-0.9%	$116.0M-3.2%	$119.9M+1.1%	$118.5M+2.5%	$115.6M+26.7%	$91.3M+23.3%	$74.0M+12.8%	$65.6M+8.9%	$60.2M+17.8%	$51.1M
Accounts Receivable	$191.9M-1.2%	$194.3M+9.9%	$176.8M+5.8%	$167.0M+19.9%	$139.3M+21.5%	$114.7M-23.8%	$150.5M+1.2%	$148.8M+5.6%	$140.9M+3.0%	$136.7M+43.6%	$95.2M+8.4%	$87.9M+35.1%	$65.0M-11.0%	$73.1M0.0%	$73.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$581.1M+10.2%	$527.4M-0.1%	$527.7M0.0%	$527.6M-8.9%	$579.0M+0.2%	$578.1M+0.5%	$575.2M-0.6%	$578.6M-6.7%	$620.1M+0.8%	$615.3M+70.8%	$360.2M+23.9%	$290.7M+52.2%	$190.9M+13.9%	$167.5M-3.5%	$173.7M
Total Liabilities	$1.6B+2.5%	$1.6B-5.8%	$1.7B-12.8%	$1.9B-8.9%	$2.1B+1.1%	$2.1B-11.6%	$2.3B-0.1%	$2.3B-9.2%	$2.6B-16.4%	$3.1B+40.1%	$2.2B+9.4%	$2.0B+63.5%	$1.2B-2.3%	$1.3B-6.9%	$1.4B
Current Liabilities	$120.9M+13.4%	$106.6M-8.9%	$117.0M-27.2%	$160.7M+12.1%	$143.4M+17.4%	$122.1M-18.5%	$149.9M+18.0%	$127.0M+3.1%	$123.2M-24.0%	$162.0M+51.9%	$106.7M+7.7%	$99.0M+17.4%	$84.4M-12.7%	$96.7M+51.2%	$63.9M
Non-Current Liabilities	$1.5B+1.7%	$1.5B-5.5%	$1.5B-11.4%	$1.7B-10.4%	$1.9B0.0%	$1.9B-11.1%	$2.2B-1.1%	$2.2B-9.8%	$2.5B-16.0%	$2.9B+39.5%	$2.1B+9.5%	$1.9B+66.8%	$1.1B-1.5%	$1.2B-9.8%	$1.3B
Long-Term Debt	$994.0M+0.2%	$992.4M-12.6%	$1.1B-15.7%	$1.3B-8.9%	$1.5B-0.2%	$1.5B-14.5%	$1.7B-3.8%	$1.8B-9.8%	$2.0B-9.2%	$2.2B+35.0%	$1.6B+4.1%	$1.6B+67.1%	$934.4M-3.8%	$970.9M-13.6%	$1.1B
Total Equity	$1.9B+2.9%	$1.8B+10.9%	$1.7B+14.4%	$1.4B-8.3%	$1.6B+16.1%	$1.4B+16.0%	$1.2B+6.9%	$1.1B-7.0%	$1.2B+43.3%	$822.5M+10.5%	$744.3M+18.6%	$627.6M+11.4%	$563.4M+17.9%	$477.9M+18.7%	$402.7M
Retained Earnings	$1.7B+12.2%	$1.6B+16.0%	$1.3B+18.5%	$1.1B-6.8%	$1.2B+20.4%	$1.0B+19.5%	$844.1M+20.3%	$701.8M-4.7%	$736.3M+85.6%	$396.7M+21.2%	$327.3M+43.9%	$227.4M+52.5%	$149.1M+95.6%	$76.2M+609.8%	$10.7M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$4.6B+33.1%	$3.5B+2.7%	$3.5B+5.0%	$3.4B+3.8%	$3.4B+3.8%	$3.4B+2.5%	$3.3B-0.3%	$3.3B-0.5%
Current Assets	$496.8M+3.4%	$431.5M-3.8%	$433.4M+14.9%	$497.4M+30.7%	$480.5M+30.3%	$448.3M+19.5%	$377.2M-4.2%	$380.7M-1.9%
Cash & Equivalents	$89.1M-36.1%	$63.9M-34.8%	$62.4M+22.6%	$119.1M+131.1%	$139.5M+307.2%	$97.9M+110.6%	$50.9M-20.0%	$51.5M-14.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$190.2M+24.2%	$159.1M+7.7%	$163.6M+8.0%	$159.0M+1.8%	$153.1M+0.7%	$147.7M+6.5%	$151.5M+1.9%	$156.2M-3.1%
Accounts Receivable	$187.4M+11.3%	$191.9M-1.2%	$190.5M+13.9%	$199.0M+21.7%	$168.4M-1.9%	$194.3M+9.9%	$167.3M-4.0%	$163.5M+3.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$650.8M+23.2%	$581.1M+10.2%	$581.2M+10.2%	$528.4M-0.2%	$528.3M0.0%	$527.4M-0.1%	$527.2M-0.1%	$529.2M+0.4%
Total Liabilities	$2.7B+68.2%	$1.6B+2.5%	$1.7B+8.1%	$1.6B+2.0%	$1.6B-3.1%	$1.6B-5.8%	$1.5B-11.4%	$1.6B-11.8%
Current Liabilities	$153.8M+40.2%	$120.9M+13.4%	$139.6M+36.1%	$134.6M+25.9%	$109.7M-3.9%	$106.6M-8.9%	$102.5M-19.5%	$106.9M-17.6%
Non-Current Liabilities	$2.5B+70.3%	$1.5B+1.7%	$1.5B+6.1%	$1.5B+0.3%	$1.5B-3.1%	$1.5B-5.5%	$1.4B-10.7%	$1.5B-11.3%
Long-Term Debt	$2.0B+102.2%	$994.0M+0.2%	$1.0B+3.4%	$993.1M-6.3%	$992.7M-9.8%	$992.4M-12.6%	$1.0B-17.4%	$1.1B-16.9%
Total Equity	$1.9B+3.3%	$1.9B+2.9%	$1.8B+2.3%	$1.8B+5.4%	$1.9B+10.4%	$1.8B+10.9%	$1.8B+11.7%	$1.7B+12.7%
Retained Earnings	$1.8B+10.7%	$1.7B+12.2%	$1.7B+12.4%	$1.6B+13.9%	$1.6B+15.3%	$1.6B+16.0%	$1.5B+16.6%	$1.4B+16.6%

PBH Cash Flow Statement

PBH quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$249.4M	$257.6M+2.4%	$251.5M+1.0%	$248.9M+8.4%	$229.7M-11.6%	$259.9M+10.3%	$235.6M+8.5%	$217.1M+14.7%	$189.3M-9.9%	$210.1M+41.3%	$148.7M-15.7%	$176.3M+12.8%	$156.3M+40.0%	$111.6M-18.9%	$137.6M+104.0%	$67.5M
Depreciation & Amortization	N/A	$31.3M+3.6%	$30.2M-1.6%	$30.7M-6.0%	$32.6M+1.7%	$32.1M+6.4%	$30.2M+4.0%	$29.0M-8.8%	$31.8M-4.9%	$33.4M+29.6%	$25.8M+8.9%	$23.7M+33.5%	$17.7M+31.5%	$13.5M+1.9%	$13.2M+23.3%	$10.7M
Stock-Based Compensation	N/A	$10.8M-2.9%	$11.2M-20.4%	$14.0M+12.9%	$12.4M+37.2%	$9.0M+5.8%	$8.5M+11.8%	$7.6M+2.8%	$7.4M-16.5%	$8.9M+9.3%	$8.1M-18.1%	$10.0M+43.9%	$6.9M+34.4%	$5.1M+36.4%	$3.8M+22.5%	$3.1M
Capital Expenditures	$14.0M	$11.2M+35.9%	$8.2M-13.9%	$9.6M+22.7%	$7.8M-19.3%	$9.6M-56.7%	$22.2M+52.8%	$14.6M+38.9%	$10.5M-16.4%	$12.5M+321.0%	$3.0M-16.6%	$3.6M-41.5%	$6.1M+120.7%	$2.8M-73.1%	$10.3M+1594.4%	$606K
Free Cash Flow	$235.4M	$246.4M+1.3%	$243.3M+1.6%	$239.4M+7.9%	$221.9M-11.3%	$250.3M+17.3%	$213.4M+5.3%	$202.6M+13.3%	$178.8M-9.5%	$197.6M+35.6%	$145.7M-15.7%	$172.7M+15.0%	$150.2M+38.0%	$108.8M-14.5%	$127.3M+90.5%	$66.8M
Investing Cash Flow	-$1.2B	-$136.8M-684.1%	-$17.5M+13.2%	-$20.1M-73.6%	-$11.6M+95.5%	-$256.5M-1053.2%	-$22.2M-34.2%	-$16.6M-129.9%	$55.4M+579.4%	-$11.6M+98.3%	-$694.6M-211.5%	-$223.0M+72.3%	-$805.3M-1289.0%	-$58.0M-616.7%	$11.2M+101.7%	-$662.2M
Financing Cash Flow	$898.7M	-$156.1M+14.3%	-$182.1M+24.5%	-$241.0M-29.7%	-$185.8M-2355.4%	-$7.6M+97.3%	-$279.4M-112.6%	-$131.4M+47.3%	-$249.3M-19.3%	-$209.0M-137.2%	$561.0M+977.2%	$52.1M-91.9%	$643.3M+1663.1%	-$41.2M+72.9%	-$152.1M-125.3%	$600.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	N/A
Share Buybacks	$121.5M	$156.3M+203.4%	$51.5M+106.0%	$25.0M-50.0%	$50.0M	$0-100.0%	$11.9M-79.1%	$56.7M+13.5%	$50.0M	$0	$0	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$70.8M-10.4%	$42.8M-30.7%	$78.3M+20.3%	$57.5M-17.6%	$79.0M+44.2%	$61.8M-7.6%	$65.1M-8.9%	$69.8M+11.8%
Depreciation & Amortization	$8.8M+14.2%	$8.4M+15.2%	$7.6M+10.5%	$7.7M-3.4%	$7.7M-5.6%	$7.3M-7.5%	$6.9M-10.2%	$7.9M+3.7%
Stock-Based Compensation	$4.0M+8.5%	N/A	$2.7M-4.4%	$1.8M-17.2%	$3.7M+7.5%	N/A	$2.9M+17.0%	$2.1M-42.1%
Capital Expenditures	$3.7M+341.9%	$5.2M+49.8%	$3.0M+93.4%	$2.1M+3.7%	$838K-27.3%	$3.5M+10.7%	$1.6M-21.5%	$2.0M-30.9%
Free Cash Flow	$67.1M-14.2%	$37.6M-35.5%	$75.3M+18.5%	$55.4M-18.3%	$78.2M+45.8%	$58.4M-8.5%	$63.5M-8.6%	$67.8M+13.9%
Investing Cash Flow	-$1.1B-54788.4%	-$3.4M+1.9%	-$128.6M-1209.7%	-$2.9M-44.5%	-$1.9M+9.0%	-$3.5M+76.8%	-$9.8M-118.3%	-$2.0M+30.9%
Financing Cash Flow	$1.0B+2907.1%	-$38.1M-231.6%	-$6.7M+87.5%	-$74.9M-46.4%	-$36.3M+44.6%	-$11.5M+83.2%	-$53.9M+16.9%	-$51.2M+4.4%
Share Buybacks	$0-100.0%	$690K-93.9%	$45.8M+1807.5%	$75.0M+534.6%	$34.8M+33.9%	$11.3M	$2.4M	$11.8M

Not reported in any period shown, so not listed: Dividends Paid.

PBH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PBH quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	54.7%-1.0pp	55.8%+0.3pp	55.5%0.0pp	55.5%-1.7pp	57.1%-0.9pp	58.0%+0.7pp	57.3%+0.4pp	56.9%+1.6pp	55.4%-1.4pp	56.7%-1.2pp	58.0%+1.0pp	56.9%+0.6pp	56.3%+0.6pp	55.7%+4.2pp	51.5%
Operating Margin	28.4%-1.2pp	29.6%-0.8pp	30.4%+32.4pp	-2.0%-32.4pp	30.4%-1.2pp	31.5%+1.3pp	30.2%+23.3pp	6.9%-13.8pp	20.7%-2.6pp	23.3%-9.0pp	32.3%+3.2pp	29.1%-2.6pp	31.7%+0.6pp	31.1%+7.8pp	23.3%
Net Margin	17.5%-1.4pp	18.9%+0.3pp	18.6%+25.9pp	-7.3%-26.2pp	18.9%+1.4pp	17.5%+2.7pp	14.8%+18.4pp	-3.7%-36.3pp	32.6%+24.7pp	7.9%-4.5pp	12.4%+1.4pp	11.0%-1.2pp	12.2%+1.6pp	10.6%+2.2pp	8.4%
Return on Equity	10.1%-1.6pp	11.7%-0.9pp	12.7%+18.3pp	-5.7%-18.7pp	13.0%+0.9pp	12.1%0.0pp	12.2%+15.4pp	-3.3%-32.1pp	28.8%+20.4pp	8.4%-5.0pp	13.4%+1.0pp	12.5%-0.4pp	12.9%-0.8pp	13.7%+4.5pp	9.2%
Return on Assets	5.5%-0.9pp	6.3%0.0pp	6.3%+8.8pp	-2.5%-8.1pp	5.6%+0.8pp	4.8%+0.8pp	4.0%+5.1pp	-1.0%-10.1pp	9.0%+7.3pp	1.8%-1.6pp	3.4%+0.4pp	3.0%-1.1pp	4.0%+0.3pp	3.8%+1.6pp	2.1%
Current Ratio	3.57-0.6x	4.20+1.0x	3.20+0.8x	2.44+0.4x	2.04-0.2x	2.21-0.2x	2.44+0.1x	2.37-0.1x	2.46+0.4x	2.06-0.3x	2.33+0.3x	2.04-0.1x	2.10+0.4x	1.70-0.6x	2.30
Debt-to-Equity	0.530.0x	0.54-0.1x	0.69-0.2x	0.930.0x	0.94-0.2x	1.09-0.4x	1.48-0.2x	1.640.0x	1.69-1.0x	2.67+0.5x	2.18-0.3x	2.49+0.8x	1.66-0.4x	2.03-0.8x	2.79
Asset Turnover	0.310.0x	0.330.0x	0.340.0x	0.340.0x	0.300.0x	0.280.0x	0.270.0x	0.280.0x	0.28+0.1x	0.230.0x	0.270.0x	0.27-0.1x	0.330.0x	0.35+0.1x	0.25
FCF Margin	22.6%+1.3pp	21.4%+0.1pp	21.3%+1.6pp	19.7%-3.4pp	23.0%+0.4pp	22.6%+1.6pp	21.0%+2.7pp	18.3%-0.7pp	19.0%+2.5pp	16.5%-4.9pp	21.4%+0.4pp	21.1%+2.8pp	18.3%-2.4pp	20.6%+5.5pp	15.2%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	51.2%-5.0pp	51.9%-5.4pp	55.5%+0.1pp	55.3%-0.2pp	56.2%+1.6pp	57.3%+2.5pp	55.5%-0.4pp	55.5%-0.4pp
Operating Margin	19.8%-9.0pp	26.8%-3.0pp	29.1%-2.6pp	29.1%-0.7pp	28.8%+1.8pp	29.8%+0.2pp	31.7%+1.0pp	29.7%-1.1pp
Net Margin	11.0%-8.0pp	19.1%+2.2pp	16.5%-4.5pp	15.4%-3.8pp	19.0%+0.7pp	16.9%-0.9pp	21.0%+2.3pp	19.2%+0.5pp
Return on Equity	1.5%-1.0pp	2.9%+0.1pp	2.5%-0.9pp	2.3%-0.8pp	2.6%-0.4pp	2.7%-0.3pp	3.4%+0.1pp	3.1%-0.4pp
Return on Assets	0.6%-0.7pp	1.5%+0.1pp	1.3%-0.5pp	1.2%-0.4pp	1.4%-0.1pp	1.5%0.0pp	1.8%+0.2pp	1.6%0.0pp
Current Ratio	3.23-1.2x	3.57-0.6x	3.11-0.6x	3.70+0.1x	4.38+1.2x	4.20+1.0x	3.68+0.6x	3.56+0.6x
Debt-to-Equity	1.05+0.5x	0.530.0x	0.560.0x	0.54-0.1x	0.54-0.1x	0.54-0.1x	0.56-0.2x	0.61-0.2x
Asset Turnover	0.060.0x	0.080.0x	0.080.0x	0.080.0x	0.070.0x	0.090.0x	0.090.0x	0.090.0x
FCF Margin	25.3%-6.1pp	13.4%-6.3pp	26.6%+4.7pp	20.2%-3.7pp	31.3%+11.3pp	19.7%-3.3pp	21.9%-2.7pp	23.9%+3.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Prestige Consumer Healthcare Inc. PBH	FY2026	$1.1B	$190.3M	17.5%	$2.3B	61/100
Amneal Pharmaceuticals, Inc. AMRX	FY2025	$3.0B	$72.1M	2.4%	$7.1B	56/100
PERRIGO COMPANY PLC PRGO	FY2025	$4.3B	-$1.4B	-33.5%	$1.9B	35/100
Indivior Pharmaceuticals, Inc. INDV	FY2025	$1.2B	$210.0M	17.0%	$4.2B	44/100
HUTCHMED (China) Limited HCM	FY2025	$548.5M	$456.9M	83.3%	$2.5B	42/100
Lantheus Holdings, Inc LNTH	FY2025	$1.5B	$233.6M	15.2%	$6.5B	71/100

Where Prestige Consumer Healthcare Inc. Ranks

Frequently Asked Questions

What is Prestige Consumer Healthcare Inc.'s annual revenue?

Prestige Consumer Healthcare Inc. (PBH) reported $1.1B in total revenue for fiscal year 2026. This represents a -4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Prestige Consumer Healthcare Inc.'s revenue growing?

Prestige Consumer Healthcare Inc. (PBH) revenue declined by 4.3% year-over-year, from $1.1B to $1.1B in fiscal year 2026.

Is Prestige Consumer Healthcare Inc. profitable?

Yes, Prestige Consumer Healthcare Inc. (PBH) reported a net income of $190.3M in fiscal year 2026, with a net profit margin of 17.5%.

What is Prestige Consumer Healthcare Inc.'s EBITDA?

Prestige Consumer Healthcare Inc. (PBH) had EBITDA of $340.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Prestige Consumer Healthcare Inc. have?

As of fiscal year 2026, Prestige Consumer Healthcare Inc. (PBH) had $63.9M in cash and equivalents against $994.0M in long-term debt.

What is Prestige Consumer Healthcare Inc.'s gross margin?

Prestige Consumer Healthcare Inc. (PBH) had a gross margin of 54.7% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Prestige Consumer Healthcare Inc.'s operating margin?

Prestige Consumer Healthcare Inc. (PBH) had an operating margin of 28.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Prestige Consumer Healthcare Inc.'s net profit margin?

Prestige Consumer Healthcare Inc. (PBH) had a net profit margin of 17.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Prestige Consumer Healthcare Inc.'s return on equity (ROE)?

Prestige Consumer Healthcare Inc. (PBH) has a return on equity of 10.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Prestige Consumer Healthcare Inc.'s free cash flow?

Prestige Consumer Healthcare Inc. (PBH) generated $246.4M in free cash flow during fiscal year 2026. This represents a 1.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Prestige Consumer Healthcare Inc.'s operating cash flow?

Prestige Consumer Healthcare Inc. (PBH) generated $257.6M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Prestige Consumer Healthcare Inc.'s total assets?

Prestige Consumer Healthcare Inc. (PBH) had $3.5B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Prestige Consumer Healthcare Inc.'s capital expenditures?

Prestige Consumer Healthcare Inc. (PBH) invested $11.2M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

Does Prestige Consumer Healthcare Inc. buy back shares?

Yes, Prestige Consumer Healthcare Inc. (PBH) spent $156.3M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Prestige Consumer Healthcare Inc. have outstanding?

Prestige Consumer Healthcare Inc. (PBH) had 47M shares outstanding as of fiscal year 2026.

What is Prestige Consumer Healthcare Inc.'s current ratio?

Prestige Consumer Healthcare Inc. (PBH) had a current ratio of 3.57 as of fiscal year 2026, which is generally considered healthy.

What is Prestige Consumer Healthcare Inc.'s debt-to-equity ratio?

Prestige Consumer Healthcare Inc. (PBH) had a debt-to-equity ratio of 0.53 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Prestige Consumer Healthcare Inc.'s return on assets (ROA)?

Prestige Consumer Healthcare Inc. (PBH) had a return on assets of 5.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Prestige Consumer Healthcare Inc.'s P/E ratio?

Prestige Consumer Healthcare Inc. (PBH) trades at 13.1x earnings, its market capitalization divided by net income of $172.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.3B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Prestige Consumer Healthcare Inc.'s price-to-sales ratio?

Prestige Consumer Healthcare Inc. (PBH) trades at 2.0x sales, its market capitalization divided by revenue of $1.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.3B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Prestige Consumer Healthcare Inc.'s Altman Z-Score?

Prestige Consumer Healthcare Inc. (PBH) has an Altman Z-Score of 2.25, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Prestige Consumer Healthcare Inc.'s Piotroski F-Score?

Prestige Consumer Healthcare Inc. (PBH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Prestige Consumer Healthcare Inc.'s earnings high quality?

Prestige Consumer Healthcare Inc. (PBH) has an earnings quality ratio of 1.35x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Prestige Consumer Healthcare Inc. cover its interest payments?

Prestige Consumer Healthcare Inc. (PBH) has an interest coverage ratio of 7.31x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Prestige Consumer Healthcare Inc.?

Prestige Consumer Healthcare Inc. (PBH) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.